Literature DB >> 10579801

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.

S Gupta1, M Srivastava, N Ahmad, D G Bostwick, H Mukhtar.   

Abstract

Aberrant or increased expression of cyclooxygenase (COX)-2 has been implicated in the pathogenesis of many diseases including carcinogenesis. COX-2 has been shown to be over-expressed in some human cancers. Employing semi-quantitative reverse transcription-PCR, immunoblotting, and immunohistochemistry we assessed COX-2 expression in samples of pair-matched benign and cancer tissue obtained from the same prostate cancer patient. Mean levels of COX-2 mRNA were 3.4-fold higher in prostate cancer tissue (n = 12) compared with the paired benign tissue. The immunoblot analysis demonstrated that as compared to benign tissue COX-2 protein was over-expressed in 10 of 12 samples examined. Immunohistochemical analysis also verified COX-2 over-expression in cancer than in benign tissue. To our knowledge, this is the first in vivo study showing an over-expression of COX-2 in prostate cancer. These data suggest that COX-2 inhibitors may be useful for prevention or therapy of prostate cancer in humans. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10579801     DOI: 10.1002/(sici)1097-0045(20000101)42:1<73::aid-pros9>3.0.co;2-g

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  133 in total

1.  COX-2 inhibitors in prostate cancer treatment--hold your horses?

Authors:  Ada S Cheung; Mathis Grossmann
Journal:  Asian J Androl       Date:  2012-05-28       Impact factor: 3.285

2.  Synthesis and Evaluation of Cytosolic Phospholipase A(2) Activatable Fluorophores for Cancer Imaging.

Authors:  Michael G Chiorazzo; Noah B Bloch; Anatoliy V Popov; Edward J Delikatny
Journal:  Bioconjug Chem       Date:  2015-10-28       Impact factor: 4.774

3.  Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies.

Authors:  Tian-Bao Huang; Yang Yan; Zhui-Feng Guo; Xiao-Long Zhang; Huan Liu; Jiang Geng; Xu-Dong Yao; Jun-Hua Zheng
Journal:  Int Urol Nephrol       Date:  2014-04-01       Impact factor: 2.370

Review 4.  Aspirin and urologic cancer risk: an update.

Authors:  Cristina Bosetti; Valentina Rosato; Silvano Gallus; Carlo La Vecchia
Journal:  Nat Rev Urol       Date:  2012-01-24       Impact factor: 14.432

Review 5.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

6.  Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men.

Authors:  Satoru Sugie; Hiromasa Tsukino; Shoichiro Mukai; Takahiro Akioka; Norihiko Shibata; Masafumi Nagano; Toshiyuki Kamoto
Journal:  Tumour Biol       Date:  2013-11-08

7.  The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.

Authors:  Tyler Etheridge; Jinning Liou; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Am J Clin Exp Urol       Date:  2018-06-15

Review 8.  Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer.

Authors:  Adam C Reese; Vincent Fradet; John S Witte
Journal:  J Nutrigenet Nutrigenomics       Date:  2009-09-23

9.  Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion.

Authors:  Dilprit Bagga; Ling Wang; Robin Farias-Eisner; John A Glaspy; Srinivasa T Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

10.  Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.

Authors:  Xi Zheng; Xiao-Xing Cui; Zhi Gao; Yang Zhao; Yong Lin; Weichung Joe Shih; Mou-Tuan Huang; Yue Liu; Arnold Rabson; Bandaru Reddy; Chung S Yang; Allan H Conney
Journal:  Cancer Prev Res (Phila)       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.